Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.57
NYSE:MCK's Cash to Debt is ranked lower than
57% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.69 vs. NYSE:MCK: 0.57 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:MCK' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.55 Max: 3.01
Current: 0.57
0.05
3.01
Equity to Asset 0.16
NYSE:MCK's Equity to Asset is ranked lower than
90% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.40 vs. NYSE:MCK: 0.16 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:MCK' s Equity to Asset Range Over the Past 10 Years
Min: 0.15  Med: 0.26 Max: 0.35
Current: 0.16
0.15
0.35
Interest Coverage 10.45
NYSE:MCK's Interest Coverage is ranked lower than
53% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 15.18 vs. NYSE:MCK: 10.45 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:MCK' s Interest Coverage Range Over the Past 10 Years
Min: 7.94  Med: 9.12 Max: 12.77
Current: 10.45
7.94
12.77
F-Score: 6
Z-Score: 4.27
M-Score: -2.52
WACC vs ROIC
7.66%
19.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 1.86
NYSE:MCK's Operating margin (%) is ranked lower than
73% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.57 vs. NYSE:MCK: 1.86 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:MCK' s Operating margin (%) Range Over the Past 10 Years
Min: 1.12  Med: 1.7 Max: 1.92
Current: 1.86
1.12
1.92
Net-margin (%) 1.15
NYSE:MCK's Net-margin (%) is ranked lower than
67% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.69 vs. NYSE:MCK: 1.15 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:MCK' s Net-margin (%) Range Over the Past 10 Years
Min: 0.77  Med: 1.03 Max: 1.18
Current: 1.15
0.77
1.18
ROE (%) 24.88
NYSE:MCK's ROE (%) is ranked higher than
96% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.04 vs. NYSE:MCK: 24.88 )
Ranked among companies with meaningful ROE (%) only.
NYSE:MCK' s ROE (%) Range Over the Past 10 Years
Min: 13.37  Med: 17.09 Max: 26.68
Current: 24.88
13.37
26.68
ROA (%) 3.95
NYSE:MCK's ROA (%) is ranked lower than
51% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.04 vs. NYSE:MCK: 3.95 )
Ranked among companies with meaningful ROA (%) only.
NYSE:MCK' s ROA (%) Range Over the Past 10 Years
Min: 2.79  Med: 4.07 Max: 4.73
Current: 3.95
2.79
4.73
ROC (Joel Greenblatt) (%) 136.77
NYSE:MCK's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.93 vs. NYSE:MCK: 136.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:MCK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 63.18  Med: 119.74 Max: 185.28
Current: 136.77
63.18
185.28
Revenue Growth (3Y)(%) 17.00
NYSE:MCK's Revenue Growth (3Y)(%) is ranked higher than
85% of the 40 Companies
in the Global Medical Distribution industry.

( Industry Median: 7.00 vs. NYSE:MCK: 17.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:MCK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.7  Med: 12.9 Max: 26.5
Current: 17
7.7
26.5
EBITDA Growth (3Y)(%) 18.40
NYSE:MCK's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 38 Companies
in the Global Medical Distribution industry.

( Industry Median: 7.90 vs. NYSE:MCK: 18.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:MCK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.7  Med: 13.3 Max: 171.6
Current: 18.4
-52.7
171.6
EPS Growth (3Y)(%) 20.00
NYSE:MCK's EPS Growth (3Y)(%) is ranked higher than
72% of the 36 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.40 vs. NYSE:MCK: 20.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:MCK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.2  Med: 13.3 Max: 87.1
Current: 20
7.2
87.1
» NYSE:MCK's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MCK Guru Trades in Q3 2015

First Pacific Advisors 47,405 sh (New)
Ken Fisher 6,433 sh (New)
Steven Cohen 4,700 sh (New)
Andreas Halvorsen 2,274,228 sh (+263.55%)
Larry Robbins 1,810,249 sh (+76.48%)
Joel Greenblatt 280,458 sh (+22.00%)
Paul Tudor Jones 8,278 sh (+20.30%)
Mario Gabelli 17,700 sh (+2.31%)
Vanguard Health Care Fund 6,471,080 sh (+2.02%)
Pioneer Investments 485,930 sh (+1.92%)
Leon Cooperman Sold Out
Scott Black 38,293 sh (-0.17%)
Jim Simons 535,500 sh (-1.99%)
Ray Dalio 26,713 sh (-10.10%)
» More
Q4 2015

MCK Guru Trades in Q4 2015

Manning & Napier Advisors, Inc 28,820 sh (New)
Jerome Dodson 80,000 sh (New)
John Paulson 8,100 sh (New)
George Soros 2,100 sh (New)
Ray Dalio 41,813 sh (+56.53%)
Andreas Halvorsen 2,761,995 sh (+21.45%)
Larry Robbins 2,192,841 sh (+21.13%)
Vanguard Health Care Fund 6,619,780 sh (+2.30%)
Jim Simons Sold Out
Steven Cohen Sold Out
Ken Fisher Sold Out
First Pacific Advisors 43,865 sh (-7.47%)
Mario Gabelli 13,925 sh (-21.33%)
Pioneer Investments 237,417 sh (-51.14%)
Scott Black 9,446 sh (-75.33%)
Paul Tudor Jones 2,028 sh (-75.50%)
Joel Greenblatt 46,915 sh (-83.27%)
» More
Q1 2016

MCK Guru Trades in Q1 2016

John Buckingham 22,294 sh (New)
Dodge & Cox 2,590 sh (New)
Arnold Van Den Berg 70,171 sh (New)
Charles Brandes 42,931 sh (New)
Wallace Weitz 57,675 sh (New)
Steven Cohen 9,200 sh (New)
Diamond Hill Capital 1,375 sh (New)
Joel Greenblatt 367,238 sh (+682.77%)
John Paulson 62,500 sh (+671.60%)
First Pacific Advisors 90,250 sh (+105.74%)
Manning & Napier Advisors, Inc 42,880 sh (+48.79%)
Vanguard Health Care Fund 7,165,280 sh (+8.24%)
Jerome Dodson 80,000 sh (unchged)
George Soros Sold Out
Andreas Halvorsen Sold Out
Scott Black 9,313 sh (-1.41%)
Mario Gabelli 12,070 sh (-13.32%)
Paul Tudor Jones 1,434 sh (-29.29%)
Larry Robbins 927,411 sh (-57.71%)
Ray Dalio 13,000 sh (-68.91%)
Pioneer Investments 11,804 sh (-95.03%)
» More
Q2 2016

MCK Guru Trades in Q2 2016

Jim Simons 97,400 sh (New)
Ronald Muhlenkamp 46,183 sh (New)
David Dreman 5,004 sh (New)
Tom Gayner 9,100 sh (New)
Steven Cohen 175,700 sh (+1809.78%)
Ray Dalio 33,359 sh (+156.61%)
Diamond Hill Capital 1,382 sh (+0.51%)
Vanguard Health Care Fund 7,165,280 sh (unchged)
Wallace Weitz 57,675 sh (unchged)
Paul Tudor Jones Sold Out
Larry Robbins Sold Out
Pioneer Investments Sold Out
Dodge & Cox Sold Out
John Buckingham 22,267 sh (-0.12%)
Arnold Van Den Berg 68,913 sh (-1.79%)
Scott Black 9,047 sh (-2.86%)
John Paulson 60,500 sh (-3.20%)
First Pacific Advisors 85,300 sh (-5.48%)
Charles Brandes 39,287 sh (-8.49%)
Manning & Napier Advisors, Inc 36,300 sh (-15.35%)
Jerome Dodson 40,000 sh (-50.00%)
Joel Greenblatt 181,378 sh (-50.61%)
Mario Gabelli 5,000 sh (-58.57%)
» More
» Details

Insider Trades

Latest Guru Trades with MCK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Distribution » Medical Distribution
Compare:NYSE:CAH, NYSE:ABC, NAS:HSIC, OTCPK:SHTDF, OTCPK:SHPMY, NAS:PDCO, NYSE:PBH, NYSE:OMI, NYSE:PMC, OTCPK:EBOSF, OTCPK:SNYR, OTCPK:ANNIF, OTCPK:NPHC, OTCPK:FZMD, OTCPK:SCVM » details
Traded in other countries:MCK.Germany, MCK.Mexico,
McKesson Corporation distributes pharmaceuticals, medical supplies and healthcare information technology that make healthcare safer while reducing costs.

McKesson Corporation is a Delaware Corporation. The Company delivers pharmaceuticals, medical supplies and healthcare information technology that make healthcare safer while reducing costs. The Company operates in two segments. The McKesson Distribution Solutions segment distributes ethical and proprietary drugs and equipment and health and beauty care products throughout North America and internationally. This segment provides specialty pharmaceutical solutions for biotech and pharmaceutical manufacturers, and practice management, technology, clinical support and business solutions to oncology and other specialty practices operating in the community setting. This segment also provides medical-surgical supply distribution, equipment, logistics and other services to healthcare providers through a network of distribution centers within the U.S. In addition, this segment sells financial, operational and clinical solutions for pharmacies (retail, hospital, alternate site) and provides consulting, outsourcing and other services. The McKesson Technology Solutions segment includes McKesson Health Solutions, which includes its InterQual clinical criteria solution, claims payment solutions and network performance tools. This segment also delivers enterprise-wide clinical, patient care, financial, supply chain, strategic management software solutions, as well as connectivity, outsourcing and other services, including remote hosting and managed services, to healthcare organizations. This segment's customers include hospitals, physicians, homecare providers, retail pharmacies and payers from North America. McKesson Distribution Solutions consists of the following businesses: North America pharmaceutical distribution and services, International pharmaceutical distribution and services and Medical Surgical distribution and services. The Company competes with other software services firms, consulting firms, shared service vendors, certain hospitals and hospital groups, payers, care management organizations, hardware vendors and internet-based companies with technology applicable to the healthcare industry.

Ratios

vs
industry
vs
history
P/E(ttm) 17.35
MCK's P/E(ttm) is ranked higher than
73% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.00 vs. MCK: 17.35 )
Ranked among companies with meaningful P/E(ttm) only.
MCK' s P/E(ttm) Range Over the Past 10 Years
Min: 8.17  Med: 18.48 Max: 38.44
Current: 17.35
8.17
38.44
Forward P/E 12.38
MCK's Forward P/E is ranked higher than
83% of the 12 Companies
in the Global Medical Distribution industry.

( Industry Median: 14.41 vs. MCK: 12.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.35
MCK's PE(NRI) is ranked higher than
71% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 21.47 vs. MCK: 16.35 )
Ranked among companies with meaningful PE(NRI) only.
MCK' s PE(NRI) Range Over the Past 10 Years
Min: 8.17  Med: 18.24 Max: 33.83
Current: 16.35
8.17
33.83
Price/Owner Earnings (ttm) 9.34
MCK's Price/Owner Earnings (ttm) is ranked higher than
93% of the 28 Companies
in the Global Medical Distribution industry.

( Industry Median: 25.44 vs. MCK: 9.34 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MCK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.5  Med: 12.47 Max: 38.54
Current: 9.34
5.5
38.54
P/B 4.08
MCK's P/B is ranked lower than
85% of the 46 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.13 vs. MCK: 4.08 )
Ranked among companies with meaningful P/B only.
MCK' s P/B Range Over the Past 10 Years
Min: 1.31  Med: 2.78 Max: 6.98
Current: 4.08
1.31
6.98
P/S 0.20
MCK's P/S is ranked higher than
87% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.91 vs. MCK: 0.20 )
Ranked among companies with meaningful P/S only.
MCK' s P/S Range Over the Past 10 Years
Min: 0.08  Med: 0.19 Max: 0.32
Current: 0.2
0.08
0.32
PFCF 8.78
MCK's PFCF is ranked higher than
81% of the 21 Companies
in the Global Medical Distribution industry.

( Industry Median: 18.30 vs. MCK: 8.78 )
Ranked among companies with meaningful PFCF only.
MCK' s PFCF Range Over the Past 10 Years
Min: 4.68  Med: 12.43 Max: 43.64
Current: 8.78
4.68
43.64
POCF 7.62
MCK's POCF is ranked higher than
80% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.31 vs. MCK: 7.62 )
Ranked among companies with meaningful POCF only.
MCK' s POCF Range Over the Past 10 Years
Min: 4.23  Med: 10.4 Max: 98.78
Current: 7.62
4.23
98.78
EV-to-EBIT 11.34
MCK's EV-to-EBIT is ranked higher than
73% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 15.31 vs. MCK: 11.34 )
Ranked among companies with meaningful EV-to-EBIT only.
MCK' s EV-to-EBIT Range Over the Past 10 Years
Min: -864.9  Med: 11.4 Max: 22.1
Current: 11.34
-864.9
22.1
EV-to-EBITDA 9.10
MCK's EV-to-EBITDA is ranked higher than
80% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.40 vs. MCK: 9.10 )
Ranked among companies with meaningful EV-to-EBITDA only.
MCK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.5  Med: 9.3 Max: 59.7
Current: 9.1
4.5
59.7
PEG 0.96
MCK's PEG is ranked higher than
83% of the 23 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.61 vs. MCK: 0.96 )
Ranked among companies with meaningful PEG only.
MCK' s PEG Range Over the Past 10 Years
Min: 0.16  Med: 1.22 Max: 8.81
Current: 0.96
0.16
8.81
Shiller P/E 29.92
MCK's Shiller P/E is ranked higher than
56% of the 18 Companies
in the Global Medical Distribution industry.

( Industry Median: 34.05 vs. MCK: 29.92 )
Ranked among companies with meaningful Shiller P/E only.
MCK' s Shiller P/E Range Over the Past 10 Years
Min: 14.98  Med: 30.1 Max: 51.97
Current: 29.92
14.98
51.97
Current Ratio 1.07
MCK's Current Ratio is ranked lower than
85% of the 46 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.56 vs. MCK: 1.07 )
Ranked among companies with meaningful Current Ratio only.
MCK' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.25 Max: 1.71
Current: 1.07
1.07
1.71
Quick Ratio 0.64
MCK's Quick Ratio is ranked lower than
85% of the 46 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.10 vs. MCK: 0.64 )
Ranked among companies with meaningful Quick Ratio only.
MCK' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 0.65 Max: 0.88
Current: 0.64
0.52
0.88
Days Inventory 31.26
MCK's Days Inventory is ranked higher than
66% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 42.62 vs. MCK: 31.26 )
Ranked among companies with meaningful Days Inventory only.
MCK' s Days Inventory Range Over the Past 10 Years
Min: 29.7  Med: 31.71 Max: 32.98
Current: 31.26
29.7
32.98
Days Sales Outstanding 34.66
MCK's Days Sales Outstanding is ranked higher than
76% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 64.02 vs. MCK: 34.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
MCK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.03  Med: 26.2 Max: 34.66
Current: 34.66
22.03
34.66
Days Payable 61.15
MCK's Days Payable is ranked lower than
51% of the 37 Companies
in the Global Medical Distribution industry.

( Industry Median: 62.84 vs. MCK: 61.15 )
Ranked among companies with meaningful Days Payable only.
MCK' s Days Payable Range Over the Past 10 Years
Min: 44.77  Med: 50.99 Max: 61.15
Current: 61.15
44.77
61.15

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.67
MCK's Dividend Yield is ranked lower than
87% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.61 vs. MCK: 0.67 )
Ranked among companies with meaningful Dividend Yield only.
MCK' s Dividend Yield Range Over the Past 10 Years
Min: 0.35  Med: 0.62 Max: 1.42
Current: 0.67
0.35
1.42
Dividend Payout 0.11
MCK's Dividend Payout is ranked higher than
94% of the 31 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.57 vs. MCK: 0.11 )
Ranked among companies with meaningful Dividend Payout only.
MCK' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.13 Max: 2
Current: 0.11
0.04
2
Dividend Growth (3y) 10.50
MCK's Dividend Growth (3y) is ranked lower than
63% of the 24 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.60 vs. MCK: 10.50 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MCK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -21.7  Med: 0 Max: 44.2
Current: 10.5
-21.7
44.2
Forward Dividend Yield 0.67
MCK's Forward Dividend Yield is ranked lower than
88% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.93 vs. MCK: 0.67 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.99
MCK's Yield on cost (5-Year) is ranked lower than
88% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.90 vs. MCK: 0.99 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MCK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.52  Med: 0.9 Max: 2.1
Current: 0.99
0.52
2.1
3-Year Average Share Buyback Ratio 0.30
MCK's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 30 Companies
in the Global Medical Distribution industry.

( Industry Median: -1.10 vs. MCK: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MCK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.6  Med: 0.2 Max: 5.7
Current: 0.3
-45.6
5.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.81
MCK's Price/Projected FCF is ranked higher than
88% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.38 vs. MCK: 0.81 )
Ranked among companies with meaningful Price/Projected FCF only.
MCK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.55  Med: 1.11 Max: 17.04
Current: 0.81
0.55
17.04
Price/DCF (Earnings Based) 0.88
MCK's Price/DCF (Earnings Based) is ranked higher than
87% of the 8 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.60 vs. MCK: 0.88 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.06
MCK's Price/Median PS Value is ranked lower than
61% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.00 vs. MCK: 1.06 )
Ranked among companies with meaningful Price/Median PS Value only.
MCK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 0.97 Max: 3.43
Current: 1.06
0.48
3.43
Price/Peter Lynch Fair Value 0.96
MCK's Price/Peter Lynch Fair Value is ranked higher than
75% of the 12 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.92 vs. MCK: 0.96 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MCK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.34  Med: 1.19 Max: 72.67
Current: 0.96
0.34
72.67
Earnings Yield (Greenblatt) (%) 8.80
MCK's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 46 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.90 vs. MCK: 8.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MCK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.5  Med: 8.7 Max: 17.6
Current: 8.8
4.5
17.6
Forward Rate of Return (Yacktman) (%) 24.17
MCK's Forward Rate of Return (Yacktman) (%) is ranked higher than
78% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 8.42 vs. MCK: 24.17 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MCK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -21.2  Med: 20.3 Max: 94.3
Current: 24.17
-21.2
94.3

More Statistics

Revenue (TTM) (Mil) $193,071
EPS (TTM) $ 9.63
Beta0.96
Short Percentage of Float1.56%
52-Week Range $148.29 - 202.20
Shares Outstanding (Mil)225.70

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 202,307 206,785
EPS ($) 13.51 14.48
EPS w/o NRI ($) 13.51 14.48
EPS Growth Rate
(3Y to 5Y Estimate)
114.80%
Dividends Per Share ($) 1.05 1.04
» More Articles for NYSE:MCK

Headlines

Articles On GuruFocus.com
Sometimes It Is Good to Buy the Biggest. But Should You Buy the Biggest Health Care Distribution Bus Jul 29 2016 
Mario Gabelli Comments on McKesson Corp Jul 26 2016 
Mario Gabelli Comments on McKesson Corp Jul 25 2016 
Wallace Weitz's Best-Performing Stocks Jul 07 2016 
Larry Robbins' Largest 1st-Quarter Sales Jun 08 2016 
Joel Greenblatt Bets on eBay, Intel, Biogen Jun 03 2016 
Beware the Financial Destruction of Overvaluation Jun 02 2016 
Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
Parnassus Fund Comments on McKesson May 09 2016 
Parnassus Fund First Quarter Commentary May 09 2016 

More From Other Websites
McKesson Launches Intelligence Hub (MKC) Sep 20 2016
Generic Drug Price Deflation Is Weighing On McKesson Shares Sep 19 2016
McKesson's Correction Is not Just a Third-Quarter Issue Sep 16 2016
McKesson downgraded by Goldman Sep 16 2016
McKesson Could Return As Much As 17.5%, Vetr Crowd Says Sep 15 2016
One Reason Why McKesson (MCK) Stock Is Under Pressure Today Sep 15 2016
German antitrust watchdog raids drugs distributors Sep 15 2016
German antitrust watchdog raids drugs distributors Sep 15 2016
Nasdaq Leads, Dow Stocks Higher As Telecom Sector Heats Up Sep 14 2016
The Dirty Little Secret Goldman Doesn't Want You To Know... Sep 14 2016
Mckesson Corp (MCK) Chairman, President & CEO John H Hammergren Sold $18.2 million of Shares Sep 13 2016
4 Cheap Pharma Stocks to Buy No Matter Who Is Elected Sep 12 2016
Ignore the Political Debate and Buy These 4 Cheap Pharma Stocks Sep 12 2016
5 Companies That Should Cut Dividends to Zero Sep 10 2016
Mckesson Corp (MCK) Chairman, President & CEO John H Hammergren Sold $18.5 million of Shares Sep 07 2016
MCKESSON CORP Files SEC form 8-K, Other Events Sep 06 2016
Billionaire Larry Robbins’ Biggest Q2 Moves in Healthcare Stocks Sep 03 2016
[$$] McKesson Ventures Joins Shyft Analytics Series B, Bets on Analytics for Pharma Aug 30 2016
Follow the pharma money Aug 25 2016
PBM trade group: Blaming payers for price hikes is red he... Aug 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)